Amicus Therapeutics (FOLD) Receives Price Target

Amicus Therapeutics (FOLD) : The most positive equity analysts on Amicus Therapeutics (FOLD) expects the shares to touch $19, whereas, the least positive believes that the stock will trade at $9 in the short term. The company is covered by 6 Wall Street Brokerage Firms. The average price target for shares are $13.33 with an expected fluctuation of $3.72 from the mean.

Amicus Therapeutics (FOLD) has an average broker rating of 1.33, which is interpreted as a Strong Buy, as rated by 6 equity analysts. Nonetheless, 5 analysts are positive on the stocks future and they recommend a Strong Buy on the stock. Nevertheless, the majority of 1 analysts consider that the stock is a Hold with neither a large upside nor a downside. Ranking by Zacks Investment Research for Coach Inc is 3, which is also a Hold.


Amicus Therapeutics (NASDAQ:FOLD): The stock was completely flat for the day, closing at $6.69 on Thursday. The flat closing masks the intraday volatility in the stock. After opening at $6.68, the stock touched an intraday high of $6.83 and a low of $6.54. Neither the bulls nor the bears asserted their supremacy at close, due to which the stock closed completely flat. The stock previously closed at $6.69. The total trading volume on Thursday was 1,276,492.

Amicus Therapeutics, Inc. is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of medicines for a range of rare and orphan diseases, with a focus on improved therapies for lysosomal storage disorders (SDs). The Companys lead product candidate is the pharmacological chaperone migalastat HCl (Galafold), a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. The Companys development programs also include ERTs for LSDs, including Fabry disease, Pompe disease and Mucopolysaccharidosis Type I (MPS I). The Companys programs in development include the small molecule pharmacological chaperone migalastat as a monotherapy for Fabry disease, SD-101 for Epidermolysis Bullosa (EB), as well as ERT products for Fabry disease, Pompe disease and MPS I.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.